

Media Release of November 26, 2025

Bellevue Asset Management strengthens its healthcare research capabilities with the recruitment of two experienced analysts

Bellevue Asset Management is expanding its healthcare expertise with the recruitment of two experienced specialists for its research team: Guy Bettschart, CFA, as Senior Healthcare Equity Research Analyst, and Dr. Markus Schweiger as Healthcare Equity Research Analyst. These new hires broaden and deepen Bellevue's research capabilities in pharmaceuticals and biotechnology in the team Healthcare Funds & Mandates.

Guy Bettschart, CFA, has more than six years of experience in the financial industry, two of which as a buy-side healthcare analyst at Kieger AG, covering a wide range of global mid- and large-cap biopharma stocks and with direct involvement in the investment process for the company's long-horizon healthcare strategies. Before that he worked for Julius Baer in Zurich as a member of its Equity Research Team. Bettschart holds a BA in Banking & Finance from the University of Zurich and an MSc in Finance from the University of Lausanne and is a CFA charterholder.

Dr. Markus Schweiger brings additional expertise in medical and biological sciences to the team. He worked for Oppenheimer & Co. in New York for two years as a biotech analyst, covering a wide range of small- and mid-cap companies active in the field of oncology and immunology. His academic credentials are a PhD in cancer biology (Vrije Universiteit Amsterdam / Massachusetts General Hospital), a dual MSc in neuroscience (Berlin/Amsterdam) and a BSc in psychology.

Terence McManus, Head of Global Healthcare / Senior Portfolio Manager, at Bellevue Asset Management: «Guy and Markus bring complementary expertise and extensive experience, adding depth to our biopharma research capabilities and investment strategies, and further solidifying our leadership in healthcare equities.»

Healthcare sector update

The healthcare sector is displaying strength as the year comes to an end. After several months of heightened uncertainty regarding the general business environment and government policies concerning the US healthcare market, the situation has clearly stabilized. Several large pharmaceutical companies have recently announced drug price agreements with the US authorities, giving them better planning accuracy. Investor sentiment has definitely improved during the past few weeks and healthcare stocks have recently outpaced the broader market.

Contact

Bellevue Asset Management AG, Theaterstrasse 12, 8001 Zurich,
Tanja Chicherio, +41 44 267 67 00, tch@bellevue.ch, www.bellevue.ch

Bellevue – Excellence in Specialty Investments

Bellevue is a specialized asset manager listed on the SIX Swiss Exchange with core competencies covering healthcare strategies, entrepreneur strategies, alternative and traditional investment strategies. Established in 1993, Bellevue, a House of Investment Ideas staffed by 90 professionals, generates attractive investment returns and creates value added for clients and shareholders alike. Bellevue managed CHF 4.8 bn in assets as of June 30, 2025.